
Adalimumab-aacf (2 Pen) Coupons & Savings Card – Discount Prices from $897.90
My prescription
Edit
40MG/0.8ML, Adalimumab-aacf (2 Pen) (1 Auto-injector Kit)
Select pharmacy

Walgreens
$897.90
COUPON PRICE
Albertsons
$915.69
COUPON PRICE
Walmart
$940.66
COUPON PRICEAdalimumab-aacf (2 Pen) savings card
Show this card to your pharmacist
Walgreens
$897.90
BIN
ID
PCN
GRP
015995
LHKNV244392
GDC
DR33
Powered by
Adalimumab-aacf (2 Pen) dosage forms
Dosage Quantity Price from Per unit 40MG/0.8ML 1 Auto-injector Kit $925.16 $925.16 40MG/0.8ML 2 Auto-injector Kits $1858.32 $929.16 40MG/0.8ML 3 Auto-injector Kits $2791.49 $930.50
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 40MG/0.8ML | 1 Auto-injector Kit | $925.16 | $925.16 |
| 40MG/0.8ML | 2 Auto-injector Kits | $1858.32 | $929.16 |
| 40MG/0.8ML | 3 Auto-injector Kits | $2791.49 | $930.50 |
Adalimumab-aacf (2 Pen) Warnings
Adalimumab-aacf is a medication that modulates the immune system, which can increase the risk of certain health issues. One significant concern is the heightened susceptibility to serious infections, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections like histoplasmosis. Patients should be tested for latent TB before starting treatment and monitored for active TB during therapy. If a serious infection develops, discontinuing the medication is advised.
Another risk involves the potential for developing malignancies, such as lymphoma and other cancers. There have been reports of a rare and aggressive type of T-cell lymphoma, known as hepatosplenic T-cell lymphoma, particularly in adolescents and young adults with inflammatory bowel disease who were treated with tumor necrosis factor (TNF) blockers, including adalimumab products.
Patients with chronic hepatitis B virus (HBV) infection may experience reactivation of the virus, which can be severe and even fatal. It's important to evaluate patients for HBV before initiating therapy and to monitor carriers during and after treatment. If HBV reactivation occurs, stopping the medication and starting antiviral therapy is recommended.
There have been rare cases of new or worsening demyelinating diseases, such as multiple sclerosis and Guillain-Barré syndrome, associated with the use of TNF blockers. Caution is advised when considering this treatment for patients with existing or recent-onset demyelinating disorders.
Serious allergic reactions, including anaphylaxis and angioedema, have been reported. If a severe allergic reaction occurs, the medication should be discontinued immediately, and appropriate therapy should be initiated.
In some instances, treatment has led to the formation of autoantibodies and, rarely, the development of a lupus-like syndrome. If symptoms suggestive of this syndrome appear, discontinuing the medication is recommended.
Patients with heart failure should use this medication with caution, as worsening or new onset of congestive heart failure has been observed. Careful monitoring is essential in these cases.
It's also important to note that live vaccines should not be administered to patients receiving this treatment. Pediatric patients should, if possible, be up to date with all immunizations before starting therapy.
Given these potential risks, it's crucial for patients to discuss their medical history and any concerns with their healthcare provider before starting adalimumab-aacf therapy.
Adalimumab-aacf (2 Pen) Side Effects
When using the Adalimumab-aacf 2 Pen, it's important to be aware of potential side effects. Common reactions include redness, itching, pain, or swelling at the injection site. These symptoms are usually mild and tend to resolve within a few days. To minimize discomfort, allow the pen to reach room temperature before injection and rotate injection sites with each dose. Some individuals may experience upper respiratory infections, such as sinusitis, as well as headaches or rashes. If these symptoms persist or worsen, consult your healthcare provider. Serious side effects, though less common, require immediate medical attention. These include signs of infection like persistent sore throat, cough, fever, chills, night sweats, or difficulty breathing. Additionally, be alert for symptoms such as unusual bruising or bleeding, pale skin, or signs of liver problems like yellowing of the skin or eyes, dark urine, or persistent nausea and vomiting. Rarely, severe allergic reactions can occur, characterized by hives, difficulty breathing, or swelling of the face, lips, or throat. If you experience any of these symptoms, seek emergency medical care immediately. Always discuss any concerns or unusual symptoms with your healthcare provider to ensure safe and effective use of Adalimumab-aacf.
